Compare Natera Inc. Common Stock (NTRA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs RLX Technology Inc — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while RLX Technology Inc trades at $1.7 (market cap $2.09B). The key difference: Natera Inc. Common Stock is far larger — about 27.3× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.85% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and RLX Technology Inc for 36 Days on average.
| NTRA | RLX | |
|---|---|---|
Market Cap | $57.03B | $2.09B |
Volume | 1,131,157 | 969,724 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $2.57 |
52-Week Low | $179.42 | $1.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $56.18B | $817.70M |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RLX Technology trades at $1.71, down 0.58% with bearish technical signals. The stock recently hit 52-week lows despite solid fundamentals including $3.62B revenue and 21.87% net margin. Recent earnings missed expectations but international expansion shows growth potential. Technical indicators show selling pressure with bearish moving averages.
RLX presents a value opportunity with discounted valuation (P/E 15.34, P/B 0.9) but faces execution risks. The bearish technical trend and earnings misses offset strong cash flow and international growth. Investors should weigh the discounted valuation against recent price weakness and margin compression concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
